Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant

Journal of Molecular Biology

Volumn 327, Issue 3, 2003, Pages 699-709

  Lee, Amanda S ^a   Galea, Charles ^a   DiGiammarino, Enrico L ^a,d   Jun, Bokkyoo ^b   Murti, Gopal ^a   Ribeiro, Raul C ^a   Zambetti, Gerard ^a,c   Schultz, Christian P ^b   Kriwacki, Richard W ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Bruker Optics Inc   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF ALABAMA IN HUNTSVILLE   (United States)

Author keywords

Amyloid like fibril; Amyloidogenesis; p53; Protein aggregation; Tetramerization domain

Indexed keywords

AMYLOID PROTEIN; CONGO RED; MUTANT PROTEIN; PROTEIN P53; THIOFLAVINE;

ALPHA HELIX; ARTICLE; BETA SHEET; CANCER; CIRCULAR DICHROISM; INFRARED SPECTROSCOPY; PATHOGENESIS; PH; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE; ROOM TEMPERATURE; STAINING; TEMPERATURE DEPENDENCE; WILD TYPE;

EID: 0037470615     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(03)00175-X     Document Type: Article

References (45)

1. Tan S.Y., Pepys M.B. Amyloidosis. Histopathology. 25:1994;403-414.
2. Ghetti B., Piccardo P., Frangione B., Bugiani O., Giaccone G., Young K., et al. Prion protein amyloidosis. Brain Pathol. 6:1996;127-145.
3. Kelly J.W. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure. 5:1997;595-600.
4. Cohen F.E., Prusiner S.B. Pathologic conformations of prion proteins. Annu. Rev. Biochem. 67:1998;793-819.
5. Guijarro J.I., Sunde M., Jones J.A., Campbell I.D., Dobson C.M. Amyloid fibril formation by an SH3 domain. Proc. Natl Acad. Sci. USA. 95:1998;4224-4228.
6. Litvinovich S.V., Brew S.A., Aota S., Akiyama S.K., Haudenschild C., Ingham K.C. Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin type III module. J. Mol. Biol. 280:1998;245-258.
7. Chiti F., Webster P., Taddei N., Clark A., Stefani M., Ramponi G., Dobson C.M. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl Acad. Sci. USA. 96:1999;3590-3594.
8. Dobson C.M., Karplus M. The fundamentals of protein folding: bringing together theory and experiment. Curr. Opin. Struct. Biol. 9:1999;92-101.
9. Porter P.L., Gown A.M., Kramp S.G., Coltrera M.D. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am. J. Pathol. 140:1992;145-153.
10. Bartek J., Bartkova J., Vojtesek B., Staskova Z., Lukas J., Rejthar A., et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 6:1991;1699-1703.
11. Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., Lafferty A.R., et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl Acad. Sci. USA. 98:2001;9330-9335.
12. DiGiammarino E.L., Lee A.S., Cadwell C., Zhang W., Bothner B., Ribeiro R.C., et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nature Struct. Biol. 9:2002;12-16.
13. Fabian H., Schultz C., Naumann D., Landt O., Hahn U., Saenger W. Secondary structure and temperature-induced unfolding and refolding of ribonuclease T1 in aqueous solution. A Fourier transform infrared spectroscopic study. J. Mol. Biol. 232:1993;967-981.
14. Schultz C.P. Illuminating folding intermediates. Nature Struct. Biol. 7:2000;7-10.
15. Fabian H., Schultz C.P. Fourier transform infrared spectroscopy in peptide and protein analysis. Meyers R.A. Encylopedia of Analytical Chemistry. 2000;1-25 Wiley, Chichester.
16. Aggeli A., Nyrkova I.A., Bell M., Harding R., Carrick L., McLeish T.C., et al. Hierarchical self-assembly of chiral rod-like molecules as a model for peptide beta sheet tapes, ribbons, fibrils, and fibers. Proc. Natl Acad. Sci. USA. 98:2001;11857-11862.
17. Nguyen J., Baldwin M.A., Cohen F.E., Prusiner S.B. Prion protein peptides induce alpha-helix to beta-sheet conformational transitions. Biochemistry. 34:1995;4186-4192.
18. Bouchard M., Zurdo J., Nettleton E.J., Dobson C.M., Robinson C.V. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci. 9:2000;1960-1967.
19. Fandrich M., Fletcher M.A., Dobson C.M. Amyloid fibrils from muscle myoglobin. Nature. 410:2001;165-166.
20. Klunk W.E., Pettegrew J.W., Abraham D.J. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 37:1989;1273-1281.
21. Levine H. Thioflavine-T interaction with amyloid β-sheet structures. Amyloid. 2:1995;1-6.
22. Creighton T.E. Proteins: Structures and Molecular Properties. 1993;W. H. Freeman, New York.
23. Bothner B., Lewis W.S., DiGiammarino E.L., Weber J.D., Bothner S.J., Kriwacki R.W. Defining the molecular basis of arf and hdm2 interactions. J. Mol. Biol. 314:2001;263-277.
24. Dobson C.M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24:1999;329-332.
25. Pervushin K., Riek R., Wider G., Wuthrich K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl Acad. Sci. 94:1997;12366-12371.
26. Sunde M., Blake C. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Advan. Protein Chem. 50:1997;123-159.
27. Dobson C.M. Protein folding and its links with human disease. Biochem. Soc. Symp. 2001;1-26.
28. Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H. Solution structure of the tetrameric minimum transforming domain of p53. Nature Struct. Biol. 1:1994;877-890.
29. Clore G.M., Ernst J., Clubb R., Omichinski J.G., Kennedy W.M., Sakaguchi K., et al. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nature Struct. Biol. 2:1995;321-333.
30. Jeffrey P.D., Gorina S., Pavletich N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 267:1995;1498-1502.
31. Padrick S.B., Miranker A.D. Islet amyloid: phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis. Biochemistry. 41:2002;4694-4703.
32. Morozova-Roche L.A., Zurdo J., Spencer A., Noppe W., Receveur V., Archer D.B., et al. Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J. Struct. Biol. 130:2000;339-351.
33. Fezoui Y., Teplow D.B. Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization. J. Biol. Chem. 277:2002;36948-36954.
34. Nielsen L., Frokjaer S., Brange J., Uversky V.N., Fink A.L. Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry. 40:2001;8397-8409.
35. Jiang X., Buxbaum J.N., Kelly J.W. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl Acad. Sci. USA. 98:2001;14943-14948.
36. Jones S., Manning J., Kad N.M., Radford S.E. Amyloid-forming peptides from beta(2)-microglobulin - insights into the mechanism of fibril formation in vitro. J. Mol. Biol. 325:2003;249-257.
37. Myers A.J., Goate A.M. The genetics of late-onset Alzheimer's disease. Curr. Opin. Neurol. 14:2001;433-440.
38. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31.
39. White J.T., Kelly J.W. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc. Natl Acad. Sci. USA. 98:2001;13019-13024.
40. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport. 10:1999;717-721.
41. McLaurin J., Yang D., Yip C.M., Fraser P.E. Review: modulating factors in amyloid-beta fibril formation. J. Struct. Biol. 130:2000;259-270.
42. Nielsen L., Khurana R., Coats A., Frokjaer S., Brange J., Vyas S., et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry. 40:2001;6036-6046.
43. Ratnaswamy G., Koepf E., Bekele H., Yin H., Kelly J.W. The amyloidogenicity of gelsolin is controlled by proteolysis and pH. Chem. Biol. 6:1999;293-304.
44. Zhu M., Souillac P.O., Ionescu-Zanetti C., Carter S.A., Fink A.L. Surface-catalyzed amyloid fibril formation. J. Biol. Chem. 277:2002;50914-50922.
45. Fabian H., Mantsch H.H., Schultz C.P. Two-dimensional IR correlation spectroscopy: sequential events in the unfolding process of the lambda cro-V55C repressor protein. Proc. Natl Acad. Sci. USA. 96:1999;13153-13158.